US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that China's National Medical Products Administration has approved Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) for use in males aged 9 to 26.
This is the first time an HPV vaccine has been authorised for use in males in China.
Gardasil is now indicated to prevent certain HPV-related cancers and diseases, including anal cancer, in males within this age group. The vaccine was previously approved for use in females in China.
Gardasil is a quadrivalent vaccine that protects against human papillomavirus types 6, 11, 16 and 18.
This approval expands the use of Gardasil in China and provides broader protection against HPV-related diseases in the country.
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Valneva secures UK approval for world's first chikungunya vaccine
Anivive Lifesciences receives USD20m in funding from Leonid Capital Partners
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies